The China FeNo testing market size was worth around USD 23.08 billion in 2022 and is predicted to grow to around USD 61.46 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.02% between 2023 and 2030.
The study examines the various forces driving and restraining the China FeNo testing market, as well as their impact on demand during the forecast period. Potential new markets for FeNo testing in China are also investigated.
Click Here to access The Full market Report : https://www.zionmarketresearch.com/report/china-feno-testing-market-size
The State of the China FeNo Testing Industry
Nitric oxide exhaled in fractions, or FeNo. Nitric oxide (NO) breath testing is a medical term for evaluating NO levels in exhaled breath. Cells lining the airways release a gas called nitrogen oxide (NO). Taking measurements of FeNO can aid in learning more about airway inflammation. Asthma is a chronic respiratory disorder characterised by inflammation and constriction of the airways; FeNO testing is routinely used during the diagnosis, monitoring, and therapy of asthma. Exhaled nitric oxide levels can be used as an indicator of airway inflammation, and more specifically eosinophilic inflammation, which is commonly associated with asthma. Testing for FeNO across the Chinese province is an economic and infrastructure priority for the sector.
Essential Considerations:
• Our research analyst has revealed that the China FeNo testing market is anticipated to expand at a CAGR of roughly 13.02% between 2023 and 2030.
• The FeNo testing market in China was estimated to be worth $23.08 billion in 2022, growing to $61.46 billion by 2030.
• Rising asthma rates in China are expected to fuel rapid expansion of the FeNo testing business in the country.
Market expansion driven by rising asthma rates
Asthma is becoming increasingly common in China, which bodes well for the FeNO testing market there. Asthma reports have increased dramatically in recent years, driving up the need for FeNo testing. The National Institute of Health (NIH) reports that asthma is a serious national health problem. In China, regular asthma attacks affect more than 4.2% of the population, or over 45 million individuals. Multiple causes have contributed to the recent increase in the rate. Environmental factors appear to play a significant role. Pollutants including particulate matter, allergies, and indoor pollutants are becoming more of a problem for the Chinese populace as the country continues to urbanise and industrialise at a breakneck pace. Moreover, China now has the worst air pollution on record. China has had a long history of air quality problems, especially in heavily populated urban regions.
Market growth is hindered by price and accessibility concerns
The high price of FeNo testing may slow the growth of local markets. Furthermore, the cost of consumables may cause overall healthcare costs to rise substantially. The cost of FeNo testing continues to be a major barrier for the FeNo testing business in China. Reports indicate that over 95% of the population has access to at least some form of healthcare; nevertheless, policies may not cover particularly severe cases of asthma.
Increased exposure will lead to new possibilities for expansion
The rising asthma awareness rate and the availability of diverse testing methods are projected to benefit the FeNo testing market in China. The need for cheaper FeNO testing is anticipated to rise in tandem with public awareness. In addition, the country’s economy has been expanding rapidly. Since more individuals will have access to basic and advanced healthcare as a result of this trend, it could be beneficial to the FeNo testing industry.
Market growth is being hindered by the absence of uniform testing processes
Since there aren’t any universally accepted testing protocols, the regional market is likely to encounter expansion problems. Another issue plaguing the FeNo testing industry in China is that doctors may interpret the results in different ways, leading patients to worry. Consistency and accuracy in FeNO testing can be achieved by standardising testing techniques, creating clear guidelines, and encouraging professional training and certification.
Get more info : https://www.zionmarketresearch.com/news/china-feno-testing-market
The China FeNO Testing Market is segmented based on product, application and region.
China FeNO Testing Market: Product Segment Analysis
● Nitric Oxide Standalone Monitor
● Nitric Oxide Handheld Monitor
● Others
China FeNO Testing Market: Application Segment Analysis
● Chronic Respiratory Symptoms
● Eosinophilic Airway Inflammation
● COPD with Mixed Inflammatory Phenotype
● Atopic Asthma
● Cystic Fibrosis
● Pulmonary Arterial Hypertension
● Eosinophilic Bronchitis
● Corticosteroid Responsiveness
● Others
Recent Changes:
• It was stated in March of 2023 that Shanghai Dongfang Hospital in China had successfully implemented the first treatment approach for refractory asthma in the country. At the same time, pre-market clinical trials were conducted at 8 other hospitals throughout the country by the hospital.
• The standard treatment for individuals with asthma was advocated for by Chinese doctors in May 2019, according to XINHUANET. They stated that just 5% of the 30,000,000 people diagnosed with asthma that same year really received appropriate care. During flying catkins seasons, they advised patients to always use masks and continue taking their medications as prescribed.
• PulmOne USA Inc. and Circassia Pharmaceuticals formed a relationship in November 2019 so that PulmOne’s MiniBox+ customers could also purchase the NIOX VERO® fractional exhaled nitric oxide (FeNO) airway inflammation measuring instrument. With locations in China, the United States, and elsewhere, Circassia is a truly international pharmaceutical and medical device conglomerate.
The China FeNo testing market is led by players like:
● Guangzhou Kingmed Diagnostics Group Co Ltd
● Hangzhou Clongene Biotech Co Ltd
● Shanghai Fosun Long March Medical Science Co Ltd
● Nanjing Norman Biological Technology Co Ltd
● Beijing Eastwest Harmony Medical Devices Co Ltd
● Guangzhou YERCON Diagnostic Co Ltd
● Aeonmed Co Ltd
● Haina Bio-Medical Technology Co Ltd
● Shanghai Hua An Medical Health Science Co Ltd
● Wuxi Medical Instrument Factory Co Ltd
● Shanghai Hengkang Medical Equipment Co Ltd
● Mindray Medical International Limited
● Nihon Kohden Corporation
● Edan Instruments Inc
● Shenzhen Comen Medical Instruments Co Ltd
● Yuyue Medical Equipment & Supply Co Ltd
● Biolight Meditech Co Ltd
● Perlong Medical Equipment Co Ltd
The growth rate in China is expected to be very significant during the next few years
As the number of people with asthma in China rises, the market for FeNo testing is expected to expand substantially. The rising number of people who suffer from asthma can mostly be attributed to changes in the environment, such as rising levels of air pollution. The air quality in this area is already poor, and it has been made worse by the presence of the Chinese chemical industry, which is one of the largest in the world. Cities in China’s first tier are expected to grow faster than any others in the country. Cities like Beijing, Shanghai, Guangzhou, and Shenzhen are included in this category. A more advanced healthcare infrastructure and a greater concentration of specialised healthcare facilities may be responsible for the faster expansion rate. More FeNo testing methods are anticipated to be provided in this section.
Get Customization Report : https://www.zionmarketresearch.com/custom/7269
About Us :
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.
Be First to Comment